Bruton's tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell
receptor signaling in the development and functioning of adaptive immunity. Growing …

B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic
leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR …

Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival
outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma …

Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing
therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune …

Summary Background Umbralisib (TGR-1202) is a novel next-generation inhibitor of
phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ), which is structurally distinct …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

Background Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients
with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituximab. We aimed …

In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …

Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has
improved outcomes for patients with hematologic malignancies, including chronic …

High-level leukemia cell expression of micro-RNA 155 (miR-155) is associated with more
aggressive disease in patients with chronic lymphocytic leukemia (CLL), including those …